[go: up one dir, main page]

WO1999033846A3 - Remedes contenant des precurseurs hydrosolubles d'amines secondaires et tertiaires, et leurs procedes d'obtention - Google Patents

Remedes contenant des precurseurs hydrosolubles d'amines secondaires et tertiaires, et leurs procedes d'obtention Download PDF

Info

Publication number
WO1999033846A3
WO1999033846A3 PCT/US1998/027659 US9827659W WO9933846A3 WO 1999033846 A3 WO1999033846 A3 WO 1999033846A3 US 9827659 W US9827659 W US 9827659W WO 9933846 A3 WO9933846 A3 WO 9933846A3
Authority
WO
WIPO (PCT)
Prior art keywords
tertiary amine
making
methods
water soluble
amine containing
Prior art date
Application number
PCT/US1998/027659
Other languages
English (en)
Other versions
WO1999033846A2 (fr
Inventor
Valentino Stella
Jeffrey P Krise
Original Assignee
Univ Kansas
Valentino Stella
Jeffrey P Krise
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas, Valentino Stella, Jeffrey P Krise filed Critical Univ Kansas
Priority to KR1020007007363A priority Critical patent/KR20010033811A/ko
Priority to NZ505515A priority patent/NZ505515A/xx
Priority to DE69822514T priority patent/DE69822514T2/de
Priority to JP2000526522A priority patent/JP2001527083A/ja
Priority to AT98965507T priority patent/ATE261730T1/de
Priority to AU20962/99A priority patent/AU754965B2/en
Priority to EP98965507A priority patent/EP1051181B1/fr
Priority to CA002317008A priority patent/CA2317008C/fr
Publication of WO1999033846A2 publication Critical patent/WO1999033846A2/fr
Publication of WO1999033846A3 publication Critical patent/WO1999033846A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur des remèdes contenant des dérivés hydrosolubles d'amines aliphatiques et aromatiques secondaires et tertiaires, ainsi que sur leurs procédés d'obtention.
PCT/US1998/027659 1997-12-31 1998-12-30 Remedes contenant des precurseurs hydrosolubles d'amines secondaires et tertiaires, et leurs procedes d'obtention WO1999033846A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020007007363A KR20010033811A (ko) 1997-12-31 1998-12-30 2차 및 3차 아민을 함유하는 약제의 물에 용해가능한프로드럭 및 그것의 제조방법
NZ505515A NZ505515A (en) 1997-12-31 1998-12-30 Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
DE69822514T DE69822514T2 (de) 1997-12-31 1998-12-30 Wasserlösliche pro-pharmaka von arzneistoffen, die ein tertiäres amin enthalten, und verfahren zu ihrer herstellung
JP2000526522A JP2001527083A (ja) 1997-12-31 1998-12-30 第二級および第三級アミン含有薬剤の水溶性プロドラッグおよびその製造方法
AT98965507T ATE261730T1 (de) 1997-12-31 1998-12-30 Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
AU20962/99A AU754965B2 (en) 1997-12-31 1998-12-30 Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
EP98965507A EP1051181B1 (fr) 1997-12-31 1998-12-30 Remedes contenant des precurseurs hydrosolubles d'amines tertiaires, et leurs procedes d'obtention
CA002317008A CA2317008C (fr) 1997-12-31 1998-12-30 Remedes contenant des precurseurs hydrosolubles d'amines tertiaires et leurs procedes d'obtention

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7009397P 1997-12-31 1997-12-31
US60/070,093 1997-12-31

Publications (2)

Publication Number Publication Date
WO1999033846A2 WO1999033846A2 (fr) 1999-07-08
WO1999033846A3 true WO1999033846A3 (fr) 1999-10-28

Family

ID=22093079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/027659 WO1999033846A2 (fr) 1997-12-31 1998-12-30 Remedes contenant des precurseurs hydrosolubles d'amines secondaires et tertiaires, et leurs procedes d'obtention

Country Status (10)

Country Link
US (1) US5985856A (fr)
EP (1) EP1051181B1 (fr)
JP (1) JP2001527083A (fr)
KR (1) KR20010033811A (fr)
AT (1) ATE261730T1 (fr)
AU (1) AU754965B2 (fr)
CA (1) CA2317008C (fr)
DE (1) DE69822514T2 (fr)
NZ (1) NZ505515A (fr)
WO (1) WO1999033846A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7582648B2 (en) 2003-07-30 2009-09-01 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US10329314B2 (en) 2016-04-04 2019-06-25 Chemocentryx, Inc. Soluble C5aR antagonists

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ES2210728T3 (es) 1997-03-07 2004-07-01 Metabasis Therapeutics, Inc. Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa.
DE19751525C2 (de) 1997-11-20 2003-02-13 Bat Cigarettenfab Gmbh Verfahren und Vorrichtung zur Regelung der Ausgangsfeuchte von Tabak
AU1915500A (en) 1998-11-20 2000-06-13 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
JP2004513183A (ja) * 2000-11-14 2004-04-30 バイタル　ヘルス　サイエンシズ　プロプライアタリー　リミティド リン酸誘導体の複合体
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
GEP20074230B (en) 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
EP2156839A1 (fr) 2002-12-11 2010-02-24 Taro Pharmaceutical Industries Ltd. Methode de traitement de troubles moteurs a l' aide de derives de l' acide barbiturique.
BRPI0409063A (pt) 2003-04-03 2006-03-28 Semafore Pharmaceuticals Inc pró medicamentos de inibidor de pi-3 cinase
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2005033079A1 (fr) 2003-09-30 2005-04-14 Eisai Co., Ltd. Agent antifongique a compose heterocyclique
DE602005025979D1 (de) * 2004-03-03 2011-03-03 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
WO2006003651A2 (fr) * 2004-07-02 2006-01-12 Taro Pharmaceutical Industries, Ltd Procede de preparation d'acide 1-methoxymethyl-5,5-diphenylbarbiturique
EP2269650A3 (fr) * 2004-08-03 2012-05-16 Vital Health Sciences Pty Ltd. Support pour l'administration entérale
WO2006046575A1 (fr) * 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. Forme amorphe d’un dérivé de cinnamide
PT1856135E (pt) 2005-01-19 2010-02-26 Rigel Pharmaceuticals Inc Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
JP4874958B2 (ja) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20090114877A1 (en) * 2005-09-13 2009-05-07 Eisai R&D Management Co., Ltd. Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
JPWO2007058305A1 (ja) * 2005-11-18 2009-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド誘導体の製造方法
US20090048448A1 (en) * 2005-11-18 2009-02-19 Ikuo Kushida Salts of cynnamide compound or solvates thereof
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
WO2007060810A1 (fr) 2005-11-24 2007-05-31 Eisai R & D Management Co., Ltd. Composes cinnamide de type morpholine
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
WO2008035726A1 (fr) 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
EP2081576A4 (fr) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame Procédé d'amélioration de la biodisponibilité pour les barbituriques non sédatifs
WO2008070149A2 (fr) * 2006-12-05 2008-06-12 Neurogesx, Inc. Promédicaments et procédés pour les fabriquer et les utiliser
PE20081791A1 (es) * 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd Dos derivados ciclicos de oxomorfolina
WO2008108384A1 (fr) * 2007-03-06 2008-09-12 Eisai R & D Management Co., Ltd. Composition contenant un dérivé de chlorométhyl phosphate avec une stabilité améliorée et son procédé de fabrication
WO2008136279A1 (fr) 2007-04-27 2008-11-13 Eisai R & D Management Co., Ltd. Sel d'un dérivé de pyridine substitué par hétérocycle ou cristaux dudit sel
TW200841879A (en) * 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
EP2147917A4 (fr) * 2007-05-16 2010-05-26 Eisai R&D Man Co Ltd Procédé de production monotope pour un dérivé de cinnamide
KR20100055456A (ko) 2007-08-31 2010-05-26 에자이 알앤드디 매니지먼트 가부시키가이샤 다환식 화합물
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
JP5567487B2 (ja) 2007-11-07 2014-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド 水分封鎖剤を使用する湿式顆粒化
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
WO2009096349A1 (fr) * 2008-01-28 2009-08-06 Eisai R & D Management Co., Ltd. Composés cristallins de cinnamide ou sels de ceux-ci
RU2010151952A (ru) * 2008-05-20 2012-06-27 Ньюроджесэкс, Инк. (Us) Водорастворимые аналоги ацетаминофена
JP5519645B2 (ja) 2008-05-20 2014-06-11 ニューロジェシックス， インコーポレイテッド カーボネートプロドラッグおよびそれを使用する方法
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
HUE026315T2 (en) 2009-01-23 2016-06-28 Rigel Pharmaceuticals Inc Preparations and methods for inhibiting the JAK pathway
JP2012176900A (ja) * 2009-06-24 2012-09-13 Eisai R & D Management Co Ltd （（ホスホノオキシ）メチル）ピリジニウム環を有するピリジン誘導体およびそれらを含有する抗真菌剤
WO2010151711A1 (fr) 2009-06-25 2010-12-29 Alkermes, Inc. Promédicaments de composés nh acides
HUE033442T2 (en) 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2454265A2 (fr) * 2009-07-17 2012-05-23 Rigel Pharmaceuticals, Inc. Composés 2,4-pyrimidine diamine deutérés et leurs promédicaments et leurs utilisations
US20110166156A1 (en) * 2010-01-07 2011-07-07 Alkermes, Inc. Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
WO2011084849A1 (fr) * 2010-01-07 2011-07-14 Alkermes, Inc. Promédicaments de la diaryldiazépine destinés au traitement d'affections neurologiques et psychologiques
ES2647361T3 (es) * 2010-01-07 2017-12-21 Alkermes Pharma Ireland Limited Profármacos de sales de amonio cuaternario
WO2011084851A1 (fr) * 2010-01-07 2011-07-14 Alkermes, Inc. Promédicaments de l'asénapine
WO2011084848A2 (fr) 2010-01-07 2011-07-14 Alkermes, Inc. Promédicaments de composés hétéroaromatiques
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
KR20130010473A (ko) 2010-03-30 2013-01-28 포스파제닉스 리미티드 경피 전달 패치
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
HRP20160478T1 (hr) * 2010-12-02 2016-07-01 The University Of Kansas Prolijekovi 6-cikloheksil-1-hidroksi-4-metilpiridin-2-(1h)-ona i njihovi derivati
ES2661574T3 (es) * 2010-12-23 2018-04-02 Alkermes Pharma Ireland Limited Profármacos de carga de múltiples PAF
WO2012122586A1 (fr) 2011-03-15 2012-09-20 Phosphagenics Limited Nouvelle composition
RS55434B1 (sr) 2011-03-18 2017-04-28 Alkermes Pharma Ireland Ltd Injektabilne farmaceutske kompozicije koje sadrže antipsihotik koji je nerastvorljiv u vodi, sorbitan laurat i polisorbat 20
WO2013044064A1 (fr) 2011-09-22 2013-03-28 Neurogesx, Inc. Conjugués d'acétaminophène, compositions en contenant et leurs méthodes d'utilisation
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
AU2012351747B2 (en) 2011-12-15 2016-05-12 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
WO2013142205A1 (fr) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant de l'alcool benzylique
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
WO2015117024A1 (fr) 2014-01-31 2015-08-06 Mayo Foundation For Medical Education And Research Nouveaux agents thérapeutiques pour le traitement du glaucome
WO2015143145A1 (fr) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
JP2017533952A (ja) 2014-11-11 2017-11-16 ザ ユニバーシティ オブ カンザス シクロピロクス、シクロピロクスオラミン又はシクロピロクスプロドラッグを用いる、膀胱癌の処置方法
CA3007587C (fr) 2015-12-09 2023-12-05 Phosphagenics Limited Formulation pharmaceutique
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
ES2983921T3 (es) 2016-12-21 2024-10-28 Avecho Biotechnology Ltd Proceso para fosforilar un alcohol complejo
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
CN111484519B (zh) * 2019-01-29 2024-04-16 连云港润众制药有限公司 磷酸二苄酯及其衍生物的制备方法
CN114380859B (zh) * 2020-10-22 2024-11-01 威智医药股份有限公司 磷酸二苄酯及焦磷酸四苄酯的制备方法
CN116399983B (zh) * 2023-06-09 2023-08-15 天津辰欣药物研究有限公司 一种利用gc-ms法检测二叔丁基氯甲基磷酸酯残留量的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2173788A (en) * 1985-03-08 1986-10-22 Leo Pharm Prod Ltd Pyridine derivatives
EP0279149A2 (fr) * 1986-11-21 1988-08-24 Aktiebolaget Hässle Dérivés du benzimidazole, leur procédé de préparation et compositions pharmaceutiques les contenant
GB2219584A (en) * 1988-05-20 1989-12-13 Haessle Ab Phosphates of benzimidazole-methanols
WO1993012124A1 (fr) * 1991-12-19 1993-06-24 Ab Astra Benzimidazoles substitues et procede de preparation et d'utilisation de ces derniers
WO1996012725A1 (fr) * 1994-10-25 1996-05-02 Schering Aktiengesellschaft Nouveaux derives de quinoxalinedione, leur preparation et leur utilisation dans des medicaments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2947773A (en) * 1956-02-01 1960-08-02 Fmc Corp Halogenated phosphorus compounds
US3998815A (en) * 1974-06-24 1976-12-21 Interx Research Corporation 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4061722A (en) * 1976-04-26 1977-12-06 Interx Research Corporation Selected quaternary ammonium salts of pilocarpine useful in reducing intraocular pressure in warm-blooded animals
US4264765A (en) * 1980-02-20 1981-04-28 Abbott Laboratories Salts of erythromycin A esters
PH23848A (en) * 1985-05-24 1989-11-23 Ciba Geigy Ag Certain phosphonic acids and derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2173788A (en) * 1985-03-08 1986-10-22 Leo Pharm Prod Ltd Pyridine derivatives
EP0279149A2 (fr) * 1986-11-21 1988-08-24 Aktiebolaget Hässle Dérivés du benzimidazole, leur procédé de préparation et compositions pharmaceutiques les contenant
GB2219584A (en) * 1988-05-20 1989-12-13 Haessle Ab Phosphates of benzimidazole-methanols
WO1993012124A1 (fr) * 1991-12-19 1993-06-24 Ab Astra Benzimidazoles substitues et procede de preparation et d'utilisation de ces derniers
WO1996012725A1 (fr) * 1994-10-25 1996-05-02 Schering Aktiengesellschaft Nouveaux derives de quinoxalinedione, leur preparation et leur utilisation dans des medicaments

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7582648B2 (en) 2003-07-30 2009-09-01 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US10329314B2 (en) 2016-04-04 2019-06-25 Chemocentryx, Inc. Soluble C5aR antagonists
US10487098B2 (en) 2016-04-04 2019-11-26 Chemocentryx, Inc. Soluble C5aR antagonists
US11254695B2 (en) 2016-04-04 2022-02-22 Chemocentryx, Inc. Soluble C5aR antagonists

Also Published As

Publication number Publication date
DE69822514D1 (de) 2004-04-22
AU2096299A (en) 1999-07-19
KR20010033811A (ko) 2001-04-25
JP2001527083A (ja) 2001-12-25
CA2317008C (fr) 2009-01-20
DE69822514T2 (de) 2005-03-24
EP1051181A2 (fr) 2000-11-15
CA2317008A1 (fr) 1999-07-08
NZ505515A (en) 2003-03-28
AU754965B2 (en) 2002-11-28
US5985856A (en) 1999-11-16
EP1051181B1 (fr) 2004-03-17
ATE261730T1 (de) 2004-04-15
WO1999033846A2 (fr) 1999-07-08

Similar Documents

Publication Publication Date Title
WO1999033846A3 (fr) Remedes contenant des precurseurs hydrosolubles d'amines secondaires et tertiaires, et leurs procedes d'obtention
EP0539588A4 (fr)
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
IL123293A0 (en) Piperidine derivatives their preparation and use
YU29599A (sh) Pesticidni 1-arilpirazoli
PL337329A1 (en) Oxazolydinone based antibacterial agents comprising a thiocarbonyl functional group
EP0338992A3 (fr) Aryl et heteroaryl bicyclodiones substituées
EP1310488A4 (fr) Composes amide bicycliques condenses et utilisations medicales associees
AU5554198A (en) 3-thiocarbamoylpyrazole derivatives as pesticides
AU2267195A (en) Dc-89 derivative
UA76409C2 (uk) Трифенілалкенові похідні і їх застосування як селективних модуляторів рецепторів естрогену
IE883463L (en) 3-£4(1-Substituted-4-piperazinyl)butyl|-4-thiazolidinones, a process for their preparation and their use as medicaments
WO2002050077A3 (fr) Triazolopyrimidines
WO1996005192A1 (fr) Derive du nouvel acide quinolone- ou naphthyridonecarboxylique ou son sel
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
EP0760368A4 (fr) Nouveau derive de pyrimidine
CA2087859A1 (fr) Derives du benzopyranne
CA2226886A1 (fr) Derives d'aminolactames n-(4-substitue-benzyl)-2
IE870207L (en) Amine derivatives.
GB2311780B (en) Pharmaceutical Piperazine Compounds
WO1998018466A3 (fr) Composes et compositions anti-inflammatoires antineurogenes et leurs procedes d'utilisation
IE823087L (en) Azetidinones.
EP0816366A4 (fr) Composes imidazothiazole
CA2024162A1 (fr) Benzazabicyclocarbamates comme nouveaux inhibiteurs de la cholinesterase
EP1020459A4 (fr) Derives d'aminocycloalkyle-pyrrolidine cis-disubstitues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2317008

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2317008

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20962/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 526522

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 505515

Country of ref document: NZ

Ref document number: 1998965507

Country of ref document: EP

Ref document number: 1020007007363

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998965507

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007007363

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 20962/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998965507

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007007363

Country of ref document: KR